Arsenal Medical focuses on developing innovative biomaterials aimed at transforming medical devices to address critical healthcare needs. Their flagship products, ResQFoam™ and NeoCast™, exemplify this commitment. ResQFoam™ is a hydrophobic foam designed to control hemorrhage in cases of abdominal trauma, which is a significant cause of preventable deaths. Recognized as a breakthrough device by the FDA, it expands within the abdominal cavity to stabilize patients until they can receive surgical intervention. On the other hand, NeoCast™ is an injectable, shear-responsive biomaterial that targets neurovascular conditions, such as chronic subdural hematomas and hypervascular tumors. It is engineered to penetrate deeply into blood vessels, providing effective occlusion while minimizing the risk of non-target embolization.

The technology behind these products is rooted in a thoughtful design process that considers the biological environment and the engineering of delivery devices. Arsenal Medical employs a cross-functional team of experts to ensure that their biomaterials meet the specific requirements of various medical applications, including trauma, neurovascular, and women's health. NeoCast™, in particular, is noted for its ability to cure into an elastomeric solid quickly, offering durable occlusion for challenging vascular conditions. The company’s ongoing research and development efforts aim to expand the utility of their biomaterials across additional therapeutic areas, reinforcing their mission to provide solutions for underserved medical conditions.

United States

Arsenal Medical is a clinical-stage company that develops biomaterials to solve challenging and underserved medical problems.  It was founded by serial entrepreneur-investor Carmichael Roberts and academic luminaries Robert Langer and George Whitesides, who shared a vision for how materials can transform medicine. 

The company’s foundational product, ResQFoam, is a life-saving intervention that addresses non-compressible intra-abdominal hemorrhage in trauma patients. It has been designated a breakthrough device by the FDA. 


Arsenal Medical

Company Details